wire - news in brief

« BACK

Life Sciences



Results 1 - 50 of 620.
1 2 3 4 5 ... 13 Next »

Life Sciences - Physics/Materials Science
22.08.2017
Treating arthritis with algae
Researchers at ETH Zurich, Empa and the Norwegian research institute SINTEF are pursuing a new approach to treating arthritis.
Life Sciences - Medicine/Pharmacology
21.08.2017
Basel Life: A Showcase for Europe's Life Sciences
Basel Life: A Showcase for Europe’s Life Sciences
Basel unites many strengths in life sciences: a strong university, strong industry and strong scientists.
Life Sciences - Medicine/Pharmacology
21.08.2017
Fundamentals of life: How centrosomes direct early embryos
Fundamentals of life: How centrosomes direct early embryos
Summer Series: Sarah Herrman is visiting Pierre GŲnczy's lab at EPFL from the University of California, Santa Cruz.
Medicine/Pharmacology - Life Sciences
17.08.2017
Hemorrhagic Fevers: Countering Inflammation to Prevent Circulatory Failure
Hemorrhagic fevers are severe viral diseases that are often fatal. Researchers from the University of Basel have now identified messenger substances of the immune system, which in infected mice lead to the development of shock. These results, published in the scientific journal Cell Host & Microbe, open up new possibilities for the development of life-saving therapies.
Environment/Sustainable Development - Life Sciences
02.08.2017
Light pollution as a new threat to pollination
Light pollution as a new threat to pollination
Media releases, information for representatives of the media Media Relations (E) Artificial light disrupts nocturnal pollination and leads to a reduced number of fruits produced by the plant. This loss of night time pollination cannot be compensated by diurnal pollinators. The negative impact of artificial light at night on nocturnal pollinators might even propagate further to the diurnal community, as ecologists of the University of Bern were able to show.
Medicine/Pharmacology - Life Sciences
27.07.2017
Malaria Already Endemic in the Mediterranean by the Roman Period
Even today, Malaria is one of the greatest medical challenges worldwide, killing hundreds of thousands of people every year. In the past, people have adapted to the threat of malaria in various ways. These methods range from interventions in the environment like draining swamps, to genetic adaptations in the human body.
Life Sciences - Social Sciences
26.07.2017
Neolithic Farmers Practiced Specialized Methods of Cattle Farming
Neolithic Farmers Practiced Specialized Methods of Cattle Farming
Swiss farmers practiced various different methods of animal farming as early as 5,400 years ago, as demonstrated by a study by researchers from the University of Basel, as well as research institutions from Germany and the UK. The study focused on the settlement Arbon Bleiche 3 on the south bank of Lake Constance.
Medicine/Pharmacology - Life Sciences
21.07.2017
Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis
Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis If approved, Actemra/RoActemra would be the first therapy for the treatment of giant cell arteritis (GCA) in Europe GCA can lead to blindness, aortic aneurysm or stroke if left untreated The positive opinion is based on the outcome of the phase III GiACTA study Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positi
Medicine/Pharmacology - Life Sciences
21.07.2017
Novartis receives positive CHMP opinion for Rydapt (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Novartis receives positive CHMP opinion for Rydapt (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) Recommendation ba
Life Sciences - Medicine/Pharmacology
20.07.2017
Innate Reaction of Hematopoietic Stem Cells to Severe Infections
If severe infections result, the body must form more white blood cells to fight off infectious agents. Hematopoietic stem cells in the bone marrow are responsible for their production. These cells, which renew themselves throughout a person's lifetime, form all cells of the hematopoietic system.
Social Sciences - Life Sciences
18.07.2017
Low-dose diazepam can increase social competitiveness
Low-dose diazepam can increase social competitiveness
EPFL scientists have discovered how low-dose anxiolytics increase the social competitiveness of high-anxious individuals by boosting the energy output of mitochondria in an area of the mammalian brain that controls motivation and reward. Psychologists speak of anxiety in two forms: ‘state' anxiety, which refers to anxiety arising from a particular situation; and ‘trait' anxiety, which refers to anxiety as part of a person's overall personality.
Medicine/Pharmacology - Life Sciences
17.07.2017
Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia
Roche's OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for peop
Medicine/Pharmacology - Life Sciences
13.07.2017
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL Recommendation based on review of CTL019 r/r B
Life Sciences
12.07.2017
Obstacle course for caterpillars
Obstacle course for caterpillars
Spines and thorns keep hungry mammals at bay - or at least, that's the conventional wisdom. However, ETH researchers have now shown that spiky growths on plants make life difficult for caterpillars too. This finding could be important for crop breeding. "Caterpillars can occasionally be skewered by the spines," says Rupesh Kariyat, a scientist at ETH Zurich's Institute of Integrative Biology.
Life Sciences
10.07.2017
Synapses in the Brain Mirror the Structure of the Visual World
Synapses in the Brain Mirror the Structure of the Visual World
The research team of Prof. Sonja Hofer at the Biozentrum, University of Basel, has discovered why our brain might be so good at perceiving edges and contours. Neurons that respond to different parts of elongated edges are connected and thus exchange information. This can make it easier for the brain to identify contours of objects.
Computer Science/Telecom - Life Sciences
07.07.2017
Eight professors appointed at ETH Zurich
Eight professors appointed at ETH Zurich
The ETH Board appointed new professors at ETH Zurich as part of its meeting of 5/6 July 2017, in accordance with the application submitted by ETH Zurich President Lino Guzzella.
Life Sciences
04.07.2017
Praying Mantises Hunt Down Birds Worldwide
Praying Mantises Hunt Down Birds Worldwide
A study by zoologists from Switzerland and the US shows: praying mantises all over the globe also include birds in their diet. The Wilson Journal of Ornithology has just published the results. Praying mantises are carnivorous insects with powerful raptorial front legs that usually depend on arthropods such as insects or spiders as their primary prey.
Medicine/Pharmacology - Life Sciences
29.06.2017
Novartis receives EU approval for first-line use of Zykadia in ALK-positive advanced non-small cell lung cancer (NSCLC)
In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival (PFS) compared to SOC chemotherapy with maintenance † Zykadia benefit was also seen in patients
Life Sciences - Medicine/Pharmacology
29.06.2017
Designed Proteins to Treat Muscular Dystrophy
Designed Proteins to Treat Muscular Dystrophy
The cell scaffolding holds muscle fibers together and protects them from damage. Individuals who suffer from muscular dystrophy often lack essential components in this cell scaffold. As a result, their muscles lack strength and become progressively weaker. The research team of Prof. Markus RŁegg at the Biozentrum, University of Basel, has now designed two proteins that stabilize the cell scaffolding link it to the muscle fiber and thereby restore muscle structure and function.
Medicine/Pharmacology - Life Sciences
28.06.2017
The gene behind follicular lymphoma
The gene behind follicular lymphoma
EPFL scientists have discovered an important gene whose loss lies behind follicular lymphoma, an incurable cancer. Follicular lymphoma is an incurable cancer that affects over 200,000 people worldwide every year. A form of non-Hodgkin lymphoma, follicular lymphoma†develops when the body starts making abnormal B-cells, which are white blood cells that in normal conditions fight infections.
Medicine/Pharmacology - Life Sciences
27.06.2017
Sandoz receives approval in Europe for Erelzi (biosimilar etanercept) to treat multiple inflammatory diseases
European Commission approves Sandoz Erelzi to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis Approval of Erelzi provides more treatment options for heal
Medicine/Pharmacology - Life Sciences
26.06.2017
Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors
Roche's emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children to be presented at the 26th International Society on Thrombosis and Haemostasis (ISTH) Meeting Roche today announced positive data from the p
Medicine/Pharmacology - Life Sciences
23.06.2017
NEJM publishes full analysis of Rydapt (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard chemotherapy improved eve
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis Kisqali (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
Novartis Kisqali (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor CHMP opinio
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data † Data evaluating 63 patients demonstrate relapse-free survival and probability of survival in a majority of patients at six months † Advances in CTL019 and ELIANA result from global CAR-T cell therapy collaboration with the University of Pennsylvania † CTL019 is manufactured us
Medicine/Pharmacology - Life Sciences
23.06.2017
Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers First in class BCL2-specific oral inhibitor represents a potential new way of treating different blood cancers Efficacy and tolerability confirmed in high-risk patients with relapsed or refractory chronic lymphocytic leukaemia, including those with 17p chromosomal de
Medicine/Pharmacology - Life Sciences
23.06.2017
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes, compared to 1.5 hour
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC) Approval provides first targeted treatment in the U
Medicine/Pharmacology - Life Sciences
21.06.2017
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance † Filing is supported by a comprehensive clinical program o
Medicine/Pharmacology - Life Sciences
19.06.2017
Sandoz receives approval in Europe for Rixathon‚? (biosimilar rituximab) to treat blood cancers and immunological diseases
European Commission approves Sandoz Rixathon ‚? to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities.
Medicine/Pharmacology - Life Sciences
16.06.2017
Bacteria Free Themselves with Molecular ‘Speargun'
Bacteria Free Themselves with Molecular ‘Speargun’
Many bacteria are armed with nano-spearguns, which they use to combat unwelcome competitors or knockout host cells.
Life Sciences - Medicine/Pharmacology
15.06.2017
Gene Transfer Keeps Bacteria Fit
Gene Transfer Keeps Bacteria Fit
Researchers at the University of Basel‚?‘s Biozentrum have discovered that Bartonella bacteria exchange genes efficiently using a domesticated virus encoded in their genome.
Medicine/Pharmacology - Life Sciences
13.06.2017
Boost for Zurich biomedicine
Boost for Zurich biomedicine
The Helmut Horten Foundation has supported Zurich's medical hub for many years. Now, a new donation to ETH will enable the strengthening of the Zurich-Ticino ‘health axis'.
Life Sciences - Medicine/Pharmacology
12.06.2017
Fighting fire blight and detecting Salmonella
Fighting fire blight and detecting Salmonella
ETH researchers have created an effective weapon against the plant disease fire blight and a new method for detection of Salmonella. Both are based on particular viruses that attack only one species of bacteria. The plant disease fire blight, caused by the bacterium Erwinia amylovora , is dreaded by fruit growers.
Life Sciences - Medicine/Pharmacology
12.06.2017
Uncovering the biology of a painful and disfiguring pediatric disease
Uncovering the biology of a painful and disfiguring pediatric disease
EPFL scientists have identified the biological mechanism behind the painful, potentially lethal, disfiguring Hyaline Fibromatosis Syndrome.‚? Image caption:‚?Loss of ANTXR2 leads to the accumulation of extracellular material in mice uterus and sterility (Left). Collagen 6 removal in mice without ANTXR2 restore uterine structure and function (Right).
Life Sciences - Mathematics
12.06.2017
Hidden patterns of brain activity
In a collaboration led by EPFL‚?‘s Blue Brain, scientists discover patterns of brain activity ‚'' never before observed ‚?- with the help of mathematics, providing insight into how neurons collectively process information. Brains of healthy rats that are the same age share many features, such as similar numbers and types of neurons present in the six layers of the cortex.
Life Sciences - History/Archeology
09.06.2017
Ancient Bones Reveal Insights Into Swiss Wild Horse Population
Researchers from the University of Basel have, for the first time, studied how regional environmental changes influenced the populations of wild horses in Switzerland 25,000 years ago. Their results show: Contrary to the wild horses in the Eurasian steppe; the Swiss population grew considerably after the end of the last Ice Age.
Medicine/Pharmacology - Life Sciences
08.06.2017
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
Data from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month ‚?
Medicine/Pharmacology - Life Sciences
07.06.2017
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43% achi
Life Sciences - Physics/Materials Science
07.06.2017
More concepts, fewer facts
More concepts, fewer facts
ETH biology lecturers have tested secondary school leavers and students to determine their knowledge of biological concepts.
Life Sciences
06.06.2017
New findings could lead to improved in vitro testing
New findings could lead to improved in vitro testing
EPFL researchers propose a new approach of performing in vitro tests on nanoparticles that could enhance a correlation to in vivo results. This involves reproducing in the lab the dynamic and fluidic variations that these particles experience in the human body. Before new nanoparticles or other nanomedicines can be injected into the human body, a whole series of tests must be conducted in the laboratory, then in living cells, and in the end on humans.
Medicine/Pharmacology - Life Sciences
05.06.2017
Phase III study showed Roche‚? s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer
Phase III study showed Roche‚??s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa lowered the risk of tumour spread or growth in the brain or central nervous system Data will be simultaneously pub
Medicine/Pharmacology - Life Sciences
04.06.2017
Novartis landmark study of Tafinlar‚? + Mekinist‚? demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
Novartis landmark study of Tafinlar‚? + Mekinist‚? demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma Study is longest follow-up to date o
Medicine/Pharmacology - Life Sciences
03.06.2017
Roche presents new data for TECENTRIQ‚? (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017
Roche presents new data for TECENTRIQ‚? (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017 Data evaluated TECENTRIQ in novel combinations across a broad range of tumours including lung, kidney and melanoma Promising Phase II combination data with TECENTRIQ plus Avastin (bevacizumab) in advanced kidney cancer First treatment-beyond-progression data from a Phase III study of cancer immunotherapy in a
Medicine/Pharmacology - Life Sciences
02.06.2017
Novartis presents updated data that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
Novartis presents updated data that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer At a subsequent
Medicine/Pharmacology - Life Sciences
02.06.2017
A new approach to combatting anxiety states, pain and inflammation
A new approach to combatting anxiety states, pain and inflammation
Media releases, information for representatives of the media Media Relations (E) Endogenous cannabinoids (endocannabinoids) play an important role in the brain and immune system. Bern researchers from the National Centre of Competence in Research (NCCR) "TransCure" have now found a new way to influence the endocannabinoid system.
Life Sciences
01.06.2017
New research tools
New research tools
At the age of 29, biotechnologist Randall Platt has already achieved a lot: more than 1,000 research laboratories around the world use a method that he developed.
Medicine/Pharmacology - Life Sciences
31.05.2017
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira * and Remicade ** Comprehensive data pac
Medicine/Pharmacology - Life Sciences
31.05.2017
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months. CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the University of Pennsylvania Novartis is committed to advancing a portfolio of next-generation CAR-T cell therapies - Novartis announced findings from a pilot study (NCT02640209) of CTL119 in combination with ibrutinib* in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who had been taking ibrutinib for at least six months and who were not in complete remission.
Medicine/Pharmacology - Life Sciences
30.05.2017
Resistant Cancer Cells: 3D Structure of a Drug Transporter Decoded
Resistant Cancer Cells: 3D Structure of a Drug Transporter Decoded
Drug resistance is not only a major problem in fighting infectious diseases. Also in the treatment of cancer it can jeopardize the success of chemotherapy.
1 2 3 4 5 ... 13 Next »

 
 
Logo Careerjet